Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury

Despite important advances in the treatment of myocardial infarction that have significantly reduced mortality, there is still an unmet need to limit the infarct size after reperfusion injury in order to prevent the onset and severity of heart failure. Multiple cardioprotective maneuvers, therapeuti...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cardiovascular medicine Vol. 8; p. 770421
Main Authors Díaz-Vesga, Magda C., Zúñiga-Cuevas, Úrsula, Ramírez-Reyes, Andrés, Herrera-Zelada, Nicolas, Palomo, Iván, Bravo-Sagua, Roberto, Riquelme, Jaime A.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 19.11.2021
Subjects
aging
cardioprotection
Cardiovascular Medicine
ischemia/reperfusion injury
mitochondria
senolytics
Online AccessGet full text

Cover

More Information
Summary:Despite important advances in the treatment of myocardial infarction that have significantly reduced mortality, there is still an unmet need to limit the infarct size after reperfusion injury in order to prevent the onset and severity of heart failure. Multiple cardioprotective maneuvers, therapeutic targets, peptides and drugs have been developed to effectively protect the myocardium from reperfusion-induced cell death in preclinical studies. Nonetheless, the translation of these therapies from laboratory to clinical contexts has been quite challenging. Comorbidities, comedications or inadequate ischemia/reperfusion experimental models are clearly identified variables that need to be accounted for in order to achieve effective cardioprotection studies. The aging heart is characterized by altered proteostasis, DNA instability, epigenetic changes, among others. A vast number of studies has shown that multiple therapeutic strategies, such as ischemic conditioning phenomena and protective drugs are unable to protect the aged heart from myocardial infarction. In this Mini-Review, we will provide an updated state of the art concerning potential new cardioprotective strategies targeting the aging heart.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Cardiovascular Therapeutics, a section of the journal Frontiers in Cardiovascular Medicine
Reviewed by: Pasquale Pagliaro, University of Turin, Italy; Petra Kleinbongard, Essen University Hospital, Germany
Edited by: Stéphanie Barrere-Lemaire, INSERM U1191 Institut de Génomique Fonctionnelle (IGF), France
These authors have contributed equally to this work
ISSN:2297-055X
2297-055X
DOI:10.3389/fcvm.2021.770421